Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sarah Cannon

Neither a doctor nor a teaching hospital

Research payments

$32,603,478

1,191 payments

Through program year 2025, Sarah Cannon is reported as receiving $32,603,478 in research payments, across 1,191 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $56,851 22
2024 Research $393,084 103
2023 Research $2,524,310 52
2022 Research $896,311 36
2021 Research $464,054 22
2020 Research $11,782,069 545
2019 Research $16,486,799 411

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $11,126,631 240 payments
  2. AstraZeneca UK Limited $11,065,985 82 payments
  3. AbbVie, Inc. $4,099,223 649 payments
  4. Pfizer Inc. $3,989,321 59 payments
  5. Acerta Pharma LLC $1,511,175 50 payments
  6. Celgene Corporation $428,874 9 payments
  7. Helsinn Healthcare SA $188,082 55 payments
  8. PharmaEssentia USA Corporation $129,639 28 payments
  9. Merck Sharp & Dohme Corporation $31,520 1 payment
  10. Regeneron Pharmaceuticals, Inc. $27,512 15 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION $9,816,735 23 payments
  2. A Phase I Dose Escalation and Expanded Cohort Study of Pf06821497 in the Treatment of Adult Patients With Relapsedrefractory Small Cell Lung Cancer SCLC Castration Resistant Prostate Cancer CRPC and Follicular Lymphoma FL $2,380,309 35 payments
  3. M16-788 $1,385,177 96 payments
  4. A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-Line Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (COLUMBIA 1) $1,352,036 3 payments
  5. A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer $1,328,263 8 payments
  6. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $996,125 46 payments
  7. A Phase 1 Openlabel Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of Pf07284892 Arry558 As A Single Agent and in Combination Therapy in Participants With Advanced Solid Tumors $907,476 11 payments
  8. A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma $845,735 8 payments
  9. A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [ less than 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST) $746,805 16 payments
  10. A Phase 1B2 Open Label Umbrella Study of Sasanlimab Combined With Anticancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Nonsmall Cell Lung Cancer Nsclc $701,537 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record